Chimeric antigen receptor engineering: A right step in the evolution of adoptive cellular immunotherapy

Jose A. Figueroa, Adair Reidy, Leonardo Mirandola, Kayley Trotter, Natallia Suvorava, Alejandro Figueroa, Venu Konala, Amardeep Aulakh, Lauren Littlefield, Fabio Grizzi, Rakhshanda Layeequr Rahman, Marjorie R. Jenkins, Breeanna Musgrove, Saba Radhi, Nicholas D'Cunha, Luke N. D'Cunha, Paul L. Hermonat, Everardo Cobos, Maurizio Chiriva-Internati

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.

Original languageEnglish (US)
Pages (from-to)154-187
Number of pages34
JournalInternational Reviews of Immunology
Issue number2
StatePublished - Mar 4 2015

Bibliographical note

Publisher Copyright:
© 2015 Informa Healthcare USA, Inc.


  • AAV: adeno-associated virus
  • ACI: adoptive cellular immunotherapy
  • AKAP4: A-kinase anchoring protein 4
  • ALL: acute lymphoblastic leukemia
  • AML: acute myeloid leukemia
  • ASP: AKAP-associated sperm protein
  • Ad: adenovirus
  • AlloSCT: allogeneic stem cell transplant
  • CAIX: carbonic anhydrase-IX
  • CAR: chimeric antigen receptor
  • CAReTC: chimeric antigen receptor-engineered T cell
  • CEA: carcinoembryonic antigen
  • CLL: chronic lymphocytic leukemia
  • CTA: cancer testis antigen
  • CTL: cytotoxic T lymphocyte
  • DC: dendritic cell
  • EBV: Epstein-Bar virus
  • ERK: extracellular signal-regulated kinase
  • FAP: fibroblast activation protein
  • FITC: fluorescein isothiocyanate
  • GVHD: graft-vs.-host disease
  • HAMA: human anti-mouse antibodies
  • HLA: human leukocyte antigen
  • HSCT: hematopoietic stem cell transplant
  • HSV: herpes simplex virus
  • HvG: host versus graft
  • IL-1, IL-2: interleukin-1, interleukin-2
  • ITR: inverted terminal repeat
  • JNK: c-Jun N-terminal kinase
  • LAK: lymphokine activated killer cell
  • Ly-CM: lymphocyte-conditioned medium
  • MHC: major histocompatibility complex
  • NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells
  • NFAT: nuclear factor of activated T cell
  • NHL: Non-Hodgkin's lymphoma
  • NK: natural killer
  • NKG2D: natural killer receptor G2D
  • PD-1: programmed death-1
  • PKA: protein A-kinase
  • RAAV: recombinant AAV
  • SIRS: systemic inflammatory response syndrome
  • SP17: sperm protein 17
  • ScFv: single-chain variable fragment
  • TAA: tumor-associating antigen
  • TCM: central memory T cell
  • TCR: T-cell receptors
  • TE: effector T cell
  • TEM: effector memory T cell
  • TH: helper T cell
  • TIL: tumor-infiltrating lymphocyte
  • TNF: tumor necrosis factor
  • TRAF: TNF receptor-associated factor
  • TRUCK: T cells redirected for universal cytokine killing
  • TSCM: stem cell memory T cell
  • Treg: regulatory T cell


Dive into the research topics of 'Chimeric antigen receptor engineering: A right step in the evolution of adoptive cellular immunotherapy'. Together they form a unique fingerprint.

Cite this